Pure Global: USA's LDT Overhaul - Navigating the FDA's New IVD Era

About this episode

This episode discusses the FDA's new regulations on Laboratory Developed Tests and their implications for clinical laboratories and patient care.

The U.S. FDA has just sent shockwaves through the diagnostics industry with a final rule to regulate Laboratory Developed Tests (LDTs) as medical devices. This decision eliminates decades of regulatory ambiguity and forces thousands of clinical laboratories into a new world of compliance, including premarket approval and quality system requirements. This episode of MedTech Global Insights breaks down the four-year transition plan, what it means for labs, and the potential impact on patient care and innovation. We explore a critical pain point: a university lab has developed a groundbreaking cancer biomarker test. Previously, they could use it for patient care immediately. Now, they face a four-year race to compile a full premarket submission, a complex and costly process they have no experience with, potentially delaying patient access to a life-saving diagnostic. Key Takeaways for This Episode: - What are the five specific stages of the FDA's new four-year phase-out plan for LDTs? - How will premarket approval requirements impact labs that have never submitted a 510(k) or PMA? - What are the new quality system (QS) requirements labs must now implement to avoid compliance action…

People in this episode

Host: Ran Chen

Topics covered

• FDA regulations
• Laboratory Developed Tests
• diagnostics industry
• patient care
• innovation
• compliance
• quality system requirements

Keywords

• FDA
• LDT
• diagnostics
• premarket approval
• quality system
• patient access
• innovation
• cancer biomarker

Mentioned in this episode

Organizations: U.S. FDA, Laboratory Developed Tests, IVD manufacturers, academic medical centers, public health labs

Books & works: cancer biomarker test

More episodes of MedTech Global Insights

• Pure Global: US AI MedTech Rules & The Global Fallout. · May 7, 2026 · 2 min
• USA MedTech M&A: Pure Global on The Deal Frenzy of 2026. · May 5, 2026 · 2 min
• Pure Global: US Cyber Rules & The MedTech Rejection Wave · May 4, 2026 · 2 min
• EU's AI-MDR Maze: Pure Global on Dual Regulation Traps · May 3, 2026 · 2 min
• Pure Global: US/EU AI Imaging & The Dual-Approval Gambit · May 2, 2026 · 2 min
• USA 510(k) Cybersecurity: Pure Global on the New Hidden Hurdles · May 1, 2026 · 2 min